Business Description
Salarius Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US33938A1051
Description
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 9.98 | |||||
| Equity-to-Asset | 0.76 | |||||
| Debt-to-Equity | 0.11 | |||||
| Debt-to-EBITDA | -0.06 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 31.3 | |||||
| 3-Year EPS without NRI Growth Rate | 33.3 | |||||
| 3-Year FCF Growth Rate | 38 | |||||
| 3-Year Book Growth Rate | -61.4 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 14-Day RSI | 44.55 | |||||
| 12-1 Month Momentum % | -23.27 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.09 | |||||
| Quick Ratio | 4.09 | |||||
| Cash Ratio | 3.51 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -60.5 | |||||
| Shareholder Yield % | -54.78 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -122.85 | |||||
| ROA % | -91.49 | |||||
| ROIC % | -1772.08 | |||||
| ROCE % | -128.36 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.82 | |||||
| Price-to-Tangible-Book | 0.82 | |||||
| EV-to-EBIT | 0.11 | |||||
| EV-to-EBITDA | 0.11 | |||||
| EV-to-FCF | 0.11 | |||||
| Price-to-Net-Current-Asset-Value | 0.83 | |||||
| Price-to-Net-Cash | 1.02 | |||||
| Earnings Yield (Greenblatt) % | 909.09 | |||||
| FCF Yield % | -220.86 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Salarius Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -5.914 | ||
| Beta | -0.32 | ||
| Volatility % | 36.93 | ||
| 14-Day RSI | 44.55 | ||
| 14-Day ATR (€) | 0.000007 | ||
| 20-Day SMA (€) | 3.008 | ||
| 12-1 Month Momentum % | -23.27 | ||
| 52-Week Range (€) | 2.736 - 6.4 | ||
| Shares Outstanding (Mil) | 1.44 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Salarius Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Salarius Pharmaceuticals Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Salarius Pharmaceuticals Inc Frequently Asked Questions
What is Salarius Pharmaceuticals Inc(FRA:FP10)'s stock price today?
The current price of FRA:FP10 is €3.01. The 52 week high of FRA:FP10 is €6.40 and 52 week low is €2.74.
When is next earnings date of Salarius Pharmaceuticals Inc(FRA:FP10)?
The next earnings date of Salarius Pharmaceuticals Inc(FRA:FP10) is 2025-02-28 Est..
Does Salarius Pharmaceuticals Inc(FRA:FP10) pay dividends? If so, how much?
Salarius Pharmaceuticals Inc(FRA:FP10) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers